Funding Briefs

NIH has calculated award rates for its individual research (ROl), career development (RCDA), academic research enhancement (AREA), and Small Business Innovation Research Phase 1 and 2 awards for fiscal year 1988. For the ROl program, the typical grant to an individual investigator, the National Eye Institute had the highest award rate among the 13 institutes, at 46%. The National Institute of Arthritis and Musculoskeletal and Skin Diseases had the lowest award rate, at 27%. The overall NIH rate

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

NIH has calculated award rates for its individual research (ROl), career development (RCDA), academic research enhancement (AREA), and Small Business Innovation Research Phase 1 and 2 awards for fiscal year 1988. For the ROl program, the typical grant to an individual investigator, the National Eye Institute had the highest award rate among the 13 institutes, at 46%. The National Institute of Arthritis and Musculoskeletal and Skin Diseases had the lowest award rate, at 27%. The overall NIH rate for the 13,863 eligible proposals was 34%. The odds are lower for career development awards, however, which go to newly established scientists. The National Institute on Aging led the pack, funding all six of its eligible proposals, while the NIH average for RCDA awards was 55%. The National Institute of Diabetes and Digestive and Kidney Diseases did best with the AREA awards, which go to scientists at smaller colleges and universities, supporting ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies